Today, while adults can legally consume cannabis recreationally, cannabis sales in Virginia are still restricted to medical use, and patients must travel to one of the five licensed providers in the commonwealth.
In March, Virginia lawmakers passed a package of bills to legalize recreational cannabis sales to people age 21 and older via a regulated market, place oversight of such sales under the Virginia Cannabis Control Authority, increase the public possession limit from one ounce to 2.5 ounces, allow delivery sales, establish new state and local cannabis taxes, and set January 1, 2027 as the launch date for sales.
Spanberger—who had campaigned on a promise to sign legislation establishing recreational cannabis sales—proposed amendments to the bill that were rejected by the General Assembly.
“I support the intent of many of the bills I am vetoing," she explained in a statement. "However, it is my responsibility as governor to make sure all new laws can be successfully implemented and protect against unintended consequences that harm Virginians."
"I look forward to continuing to work with bill patrons, state and local leaders, and advocates on legislation addressing these issues in the future," the governor said.
Marijuana Moment reported that Spangberger sought to delay the start of sales by six months, increase taxes, and institute new criminal penalties for cannabis consumers.
“Once again, Virginia’s efforts to establish a safe, regulated, and equitable adult-use cannabis marketplace has been halted despite years of work, public input, and broad recognition that the status quo is failing Virginians," state Sen. Lashrecse Aird (D-63), who sponsored one of the bills, said in a statement Tuesday.
“The governor’s decision leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market hurting our communities, harming our youth, and putting adults at risk," she added.
Del. Paul Krizek (D-16), who sponsored the House of Delegates version of the sales bill, said, “Five years ago, Virginia legalized cannabis in recognition that the War on Drugs has caused disproportionate harm to Black families and communities."
“The question now is whether Virginia will continue allowing an unregulated illegal market to thrive, or finally establish a safe, transparent system that protects consumers, keeps products away from children, and keeps our commitment to ending racially discriminatory marijuana policing in Virginia," he added.
JM Pedini, development director for the advocacy group National Organization for the Reform of Marijuana Laws and executive director for Virginia NORML, told Marijuana Moment that Spanberger's veto is “a profound disappointment to the many Virginia voters who believed her when she said on the campaign trail that she supported establishing a regulated adult-use cannabis market.”
“It is also a slap in the face to the years of serious work undertaken by lawmakers, policy experts, advocates, public health stakeholders, and regulators who spent more than half a decade researching, debating, and carefully crafting this legislation,” Pedini added. “Rather than build upon that work, the governor dismissed it in favor of out-of-touch proposals to recriminalize cannabis consumers that lawmakers rightly rejected.”
Chelsea Higgs Wise, executive director of the Richmond-based nonprofit Marijuana Justice, said in a statement that "for five years, Virginia has been stuck in a limbo where adults can legally possess, share, and grow cannabis, but there is still no regulated way to purchase it."
"By rejecting the retail bill," Wise added, "the governor has chosen to extend that chaos rather than move us toward a transparent, accountable retail system that centers public health, public safety, and justice."
Twenty-four states have legalized recreational marijuana, while 16 states allow medical use of the plant. Last month, the US Department of Justice began reclassifying cannabis from Schedule I—a category that includes dangerous drugs like heroin, LSD, and MDMA to Schedule III, which includes codeine, ketamine, anabolic steroids, and testosterone.
